|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Robert E. Ward||Chairman & CEO||N/D||N/D||1958|
|Dr. Silvia Noiman||Founder & Director||N/D||N/D||1956|
|Mr. Gregory L. Weaver CPA, M.B.A.||Chief Financial Officer||N/D||N/D||1956|
|Dr. Gregory Williams||COO & Interim Chief Medical Officer||N/D||N/D||1959|
|Ms. Barbara Ryan||Investor Relations Officer||N/D||N/D||N/D|
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel ribonucleic acid for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which has completed Phase 1 clinical trial that focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
L'ISS Governance QualityScore di Eloxx Pharmaceuticals, Inc. al 29 luglio 2019 è 4. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 6; diritti degli azionisti: 1; retribuzione: 7.